In the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial, recruiting 2368 patients with T2D and coronary artery disease, the incident HF did not differ significantly between patients receiving insulin-sensitization therapy (metformin or thiazolidinediones) (19.4%) and those receiving insulin-provision therapy (insulin or sulfonylurea) (16.6%, p = 0.09) [79]. Here, INS is linked to coronary artery disorder.